Preclinical Data Show Efficacy of Elutia’s Antibiotic-Eluting BioEnvelope

Elutia Inc. is reporting encouraging study results for its U.S. Food and Drug Administration (FDA)-cleared antibiotic-eluting biologic envelope.

Preclinical data demonstrate that EluPro clears bacterial contamination associated with cardiovascular implantable electronic devices (CIEDs). Results published in Frontiers in Drug Delivery show that EluPro reduced bacterial colonization in an animal model with minimal systemic antibiotic exposure.
 
The FDA cleared EluPro for use with CIEDs and has been approved for use with additional devices, including neuromodulators and neurostimulators for pain management, epilepsy, incontinence, and sleep apnea. The first patient implant of EluPro was completed in September.
 
“EluPro is a biologic envelope that has the ability to improve implant stability and reduce device migration. This latest study highlights EluPro’s potential to address the risk of bacterial contamination, a major concern in CIED procedures,” said Dr. M. Rizwan Sohail, professor of Medicine at Baylor College of Medicine and an author on the publication. “Additionally, recent clinical findings suggest that EluPro may help minimize scarring and fibrosis around the implant, potentially making reoperation easier. Together, these insights highlight EluPro’s comprehensive approach to addressing a range of challenges associated with implantable devices.”
 
The studies were conducted using a well-established rabbit model of CIED infection. Devices were implanted with either EluPro or a non-antibiotic control envelope, and bacterial species were introduced. Implant sites were monitored for signs of infection for one week, and explanted envelopes were assessed for bacterial presence. The results revealed that none of the animals receiving EluPro exhibited signs of infection, whereas animals in the control group developed fevers, required supportive care, or experienced premature death. Additionally, EluPro demonstrated significant bacterial reduction at the implant sites, achieving complete eradication of methicillin-resistant staphylococcus aureus, commonly known as MRSA, and other strains. Furthermore, EluPro provided sustained local antibiotic release for over a week with minimal systemic exposure, a key benefit of local drug delivery.
 
“We believe these results greatly reinforce EluPro’s potential to provide enhanced infection control for CIED procedures,” Elutia Chief Scientific Officer Michelle LeRoux Williams, Ph.D., stated. “As the first FDA-cleared biologic antibiotic-eluting envelope, EluPro represents a significant step forward in implantable device protection. With our recent milestone of the first human implant, we are preparing for the commercial launch of EluPro in January 2025.”
 
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine.